Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Here's Why You Should Retain Haemonetics In Your Portfolio Now

By Zacks Investment ResearchStock MarketsFeb 17, 2020 08:52PM ET
Here's Why You Should Retain Haemonetics In Your Portfolio Now
By Zacks Investment Research   |  Feb 17, 2020 08:52PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Haemonetics Corporation (NYSE:HAE) is progressing well with its growth strategies like the expansion of the product portfolio within its plasma and Hemostasis Management franchise. However, economic uncertainty and tough competition are likely to offset the positives to some extent.

The leader of blood management solutions’, with a market capitalization of $6.08 billion, earnings growth is estimated to be 13.5% over the next five years. Also, the company has a trailing-four quarter positive earnings surprise of 21%, on average.

Over the past year, the stock has outperformed its industry. The stock rallied 37.5% compared with the industry’s 10.5% rise.

Let’s delve deeper into other factors that substantiate its Zacks Rank #3 (Hold).

Potential of Plasma: Haemonetics has been witnessing strong growth in the Plasma franchise for quite some time. In the fiscal third quarter, the largest business segment of the company witnessed 6.9% improvement on strong growth within North America, driven by the underlying demand for plasma-based medicines, software upgrades and competitive conversions.

The company continued to benefit from the NexSys device and NexLynk donor management software (DMS), backed by increased customer adoptions. Haemonetics is optimistic about the prospects of its Plasma business and projects 13-15% segmental growth for fiscal 2020.

Potential of Hemostasis Management: Under the Hospital business, Hemostasis Management has witnessed strong growth over the recent past. The Hospital business witnessed 6.4% growth in the third quarter, wherein organic revenue growth for the Hemostasis Management product line was 19.8%.

The TEG Hemostasis Analyzer system continues to be the growth driver for the company, registering 20% improvement in the third quarter on improved utilization, market share gains and product launches such as the TEG 6s PlateletMapping cartridge and the U.S. trauma indication. These factors are expected to continue driving growth for the company’s Hospital business.

Upbeat Guidance: Haemonetics expects revenue growth of 3-5% for fiscal 2020. The company also anticipates yearly organic revenue growth at 6-8%. Further, it raised its 2020 adjusted earnings per share guidance. This indicates the continuation of its bullish trend through the rest of fiscal 2020.

However, there are a few downsides marring growth prospects of the company.

Economic Uncertainty: The uncertain economic scenario continues to pose a challenge for Haemonetics. The company has been progressing with blood management solutions even though the attempt is negatively impacted by economic challenges. Moreover, a stronger dollar, causing significant currency fluctuations, has been affecting its outcome over the past few quarters and no respite is expected in the near term.

Competitive Landscape: Haemonetics operates in a very competitive environment, for both manual and automated systems, which includes companies like MAK Systems, Medtronic (NYSE:MDT), Fresenius, MacoPharma and Terumo. Slower-than-expected product adoption by customers, especially the American Red Cross, might reduce Haemonetics’ revenues and profit.

Estimate Trend

The company is witnessing a positive estimate revision trend for 2020. Over the past 30 days, the Zacks Consensus Estimate for its earnings has inched up 1.4% to 75 cents per share.

The Zacks Consensus Estimate for the company’s fourth-quarter fiscal 2020 revenues is pegged at $249.2 million, suggesting 0.04% fall from the year-ago reported number.

Stocks Worth a Look

A few better-ranked stocks from the broader medical space are Hill-Rom (NYSE:HRC) , Stryker (NYSE:SYK) and ResMed (NYSE:RMD) . While ResMed currently sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Hill-Rom has a projected long-term earnings growth rate of 11.1%.

Stryker has an expected long-term earnings growth rate of 9.9%.

ResMed has a long-term earnings growth rate of 11.9%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Stryker Corporation (SYK): Free Stock Analysis Report

Haemonetics Corporation (HAE): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

Hill-Rom Holdings, Inc. (HRC): Free Stock Analysis Report

Original post

Zacks Investment Research
Here's Why You Should Retain Haemonetics In Your Portfolio Now

Related Articles

Here's Why You Should Retain Haemonetics In Your Portfolio Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email